Positioning & Distribution Will Determine the Winning Healthcare AI Startups, Investor Says
In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workfl [...]
Across the Prostate Cancer Continuum: Translating ArteraAI’s Biopsy Model in Localized Disease and Beyond
Since launching the ArteraAI Prostate Test, Artera has used multimodal artificial intelligence (MMAI) algorithms to help thou [...]
How Marc Benioff paired experts in AI and prostate cancer, leading to a new way to fine-tune treatments
The company was formed in September 2021 and two years later lined up $90 million.
FDA just signed off on AI predicting long-term cancer outcomes
The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effecti [...]
FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool
The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artific [...]
Identifying Patients Who Will Benefit From Intensified Prostate Cancer Treatment
Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therape [...]
AI Tool Accurately Predicts Prostate Cancer Outcomes Across Racial Groups
Mack Roach III, MD, professor of radiation oncology, medical oncology, and urology at the University of California, San Franc [...]
Multimodal AI Shows No Evidence of Bias in Prostate Cancer Study
The study evaluated the performance of a multimodal artificial intelligence model to close gaps in care and validate that AI [...]
Artera Bullish on Prostate Cancer Test Following NYS Approval, Impending Registry Study
NEW YORK – Startup firm Artera is continuing to make commercial progress with its artificial intelligence-based prostate canc [...]